NTRK2 and central nervous system cancer: Despite differing tumor behavior in younger patients compared to adults, entrectinib too has been successfully employed in small numbers of fusion-positive pediatric and infantile CNS tumors including gliomas per preliminary data from the STARTRK-NG.13,14 One patient with a similar BCR-NTRK2 fusion was included in the STARTRK-NG data with stable disease achieved.